Inicio
Explorar
nav.journalClub
Tendencias
Más
synapse
⌘+K
Idioma
Español
Español
April 10, 2026
Open Access
Flare risk after oral glucocorticoid bridging with methotrexate or intra‐articular bridging with triple therapy in early rheumatoid arthritis
KL
Kristina Lend
Karolinska Institutet
JT
Jos W. R. Twisk
Amsterdam University Medical Centers
FK
Frieda A. Koopman
Amsterdam University Medical Centers
Ver todo
Puntos clave
This research aims to assess the risk of flares in early rheumatoid arthritis patients using different bridging therapies.
Clinical trial with specific identifiers (EudraCT 2011-004720-35, ClinicalTrials.gov NCT01491815)
Comparison of oral glucocorticoids with methotrexate versus intra-articular triple therapy
Evaluation of flare incidents in participants during treatment.
Identification of flare risk levels associated with each bridging method
Comparison outcomes highlighting differences in flare rates
Potential recommendations for improved management strategies.
Resumen
EudraCT 2011-004720-35; ClinicalTrials.gov NCT01491815.
Leer artículo completo
externamente
Mark Helpful
Me gusta
Save
Guardar
Relay
Compartir
Ver artículo completo
Mark Helpful
Me gusta
Save
Guardar
Relay
Compartir
Ver artículo completo
Flare risk after oral glucocorticoid bridging with methotrexate or intra‐articular bridging with triple therapy in early rheumatoid arthritis | Synapse
Cite This Study
Copy
Lend et al. (Mon,) studied this question.
synapsesocial.com/papers/69d893c96c1944d70ce04bee
https://doi.org/https://doi.org/10.1111/joim.70094